Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification-Reference-Cited by-同舟云学术

Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification

Published:2021-04-07 Issue:8 Volume:68 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Berthold Frank¹^ORCID,Rosswog Carolina²³,Christiansen Holger⁴,Frühwald Michael⁵^ORCID,Hemstedt Nadine²³,Klingebiel Thomas⁶,Fröhlich Birgit⁷,Schilling Freimut H.⁸,Schmid Irene⁹,Simon Thorsten¹,Hero Barbara¹^ORCID,Fischer Matthias²³,Ernst Angela¹⁰

Affiliation:

1. Department of Pediatric Oncology and Hematology University of Cologne Cologne Germany

2. Department of Experimental Pediatric Oncology University of Cologne Cologne Germany

3. Center for Molecular Medicine, Medical Faculty University of Cologne Cologne Germany

4. Department of Pediatric Oncology and Hematology University of Leipzig Leipzig Germany

5. Swabian Children's Cancer Center, Children's Hospital University Hospital Augsburg Augsburg Germany

6. Department of Children and Adolescents, University Hospital Goethe University Frankfurt (Main) Frankfurt Germany

7. Department of Pediatric Oncology and Hematology University of Munster Munster Germany

8. Department of Pediatric Oncology and Hematology Olgahospital Stuttgart Stuttgart Germany

9. Department of Pediatric Hematology and Oncology and Hematology, Dr. von Hauner Children's Hospital Ludwig‐Maximilians‐University Munich Munich Germany

10. Institute of Medical Statistics and Computational Biology University of Cologne Cologne Germany

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29038

Reference24 articles.

1. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

2. SPECIAL PATTERN OF WIDESPREAD NEUROBLASTOMA WITH A FAVOURABLE PROGNOSIS

3. Neuroblastoma stage 4S: a multifocal stem-cell disease of the developing neural crest

4. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation

5. A mechanistic classification of clinical phenotypes in neuroblastoma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic ALK alterations in primary and relapsed neuroblastoma;British Journal of Cancer;2023-02-17

2. Clinical outcomes following resection of paraspinal ganglioneuromas: a case series of 15 patients;Journal of Neurosurgery: Spine;2022-07-01

3. Osteogenesis Imperfecta/Ehlers–Danlos Overlap Syndrome and Neuroblastoma—Case Report and Review of Literature;Genes;2022-03-25

4. Neuroblastoma survivors at risk for developing subsequent neoplasms: A systematic review;Cancer Treatment Reviews;2022-03

5. SAP30, an oncogenic driver of progression, survival, and drug resistance in high-risk neuroblastoma;Molecular Therapy - Nucleic Acids;2022-03